for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DAIICHI SANKYO COMPANY, LIMITED

4568.T

Latest Trade

7,152.00JPY

Change

26.00(+0.36%)

Volume

1,909,000

Today's Range

7,074.00

 - 

7,224.00

52 Week Range

3,277.00

 - 

7,358.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
7,126.00
Open
7,111.00
Volume
1,909,000
3M AVG Volume
36.25
Today's High
7,224.00
Today's Low
7,074.00
52 Week High
7,358.00
52 Week Low
3,277.00
Shares Out (MIL)
647.89
Market Cap (MIL)
5,070,849.00
Forward P/E
51.57
Dividend (Yield %)
0.98

Next Event

Dividend For 4568.T - 35.0000 JPY

Latest Developments

More

Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) In Japan With Regulatory Submission In Her2 Positive Metastatic Breast Cancer

Daiichi Sankyo Says U.S. FDA Approved Co's Turalio For Treatment Of Select Patients With TGCT, A Rare And Debilitating Tumor

FDA Approves Daiichi Sankyo's Turalio For Treatment Of Select Patients With TGCT, A Rare And Debilitating Tumor

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About DAIICHI SANKYO COMPANY, LIMITED

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.

Industry

Biotechnology & Drugs

Contact Info

Daiichi Sankyo Bldg. A/B Kan

3-5-1, Nihombashi Hon-cho

+81.3.62251111

https://www.daiichisankyo.co.jp/

Executive Leadership

Joji Nakayama

Chairman of the Board, Chief Executive Officer, Representative Director

Sunao Manabe

Executive President, President, Chief Operating Officer, Representative Director

Toshiaki Sai

Chief Financial Officer, Executive Vice President, Vice President, Chief Director of Business Strategy, Representative Director

Kentaro Takamura

Managing Executive Officer, Director of Finance & Accounting in Main Business Strategy Unit

Satoru Kimura

Senior Managing Executive Officer, Chief Director of Pharmaceutical Sales

Key Stats

2.18 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

1.0K

2018

1.0K

2019

0.9K

2020(E)

1.0K
EPS (JPY)

2017

79.630

2018

91.310

2019

144.200

2020(E)

138.679
Price To Earnings (TTM)
41.16
Price To Sales (TTM)
5.32
Price To Book (MRQ)
3.69
Price To Cash Flow (TTM)
31.56
Total Debt To Equity (MRQ)
17.90
LT Debt To Equity (MRQ)
17.87
Return on Investment (TTM)
6.80
Return on Equity (TTM)
5.71

Latest News

U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor

The U.S. Food and Drug Administration on Friday approved Daiichi Sankyo Co Ltd's treatment for adult patients with a type of rare, non-cancerous tumor affecting joints and limbs.

U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor

The U.S. Food and Drug Administration (FDA) on Friday approved Daiichi Sankyo Co Ltd's treatment for adult patients with a type of rare, non-cancerous tumor usually affecting joints and limbs.

FDA declines to approve Daiichi Sankyo's blood cancer treatment

Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

FDA declines to approve Daiichi Sankyo's blood cancer treatment

Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

Daiichi Sankyo looking to sell OTC drug unit for about $900 million: Nikkei Business

Japan's Daiichi Sankyo Co Ltd is in talks with several companies to sell its wholly owned over-the-counter (OTC) drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.

Daiichi Sankyo looking to sell OTC drug unit for about $900 mln - Nikkei Business

Japan's Daiichi Sankyo Co is in talks with several companies to sell its wholly owned over-the-counter drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.

FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment

Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

FDA advisory panel votes against Daiichi Sankyo's cancer treatment

Independent experts on an FDA advisory panel on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

AstraZeneca-Daiichi breast cancer treatment shows promise in latest study

An experimental breast cancer drug being developed by British drugmaker AstraZeneca and Japan's Daiichi Sankyo's met its main goal in a mid-stage study, bolstering their position in a highly competitive oncology market.

AstraZeneca-Daiichi Sankyo breast cancer drug shows promise

British drugmaker AstraZeneca and Japan's Daiichi Sankyo said on Wednesday their experimental treatment for breast cancer met its key goal in a mid-stage study, bolstering their defences in a highly competitive oncology market.

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.

Nikkei up on U.S.-China trade talk optimism; Daiichi Sankyo jumps

Japan's Nikkei rose on Friday on optimism about the latest round of U.S.-China trade talks, with cyclical sectors such as shipping and machinery advancing on the last day of the Japanese fiscal year.

AstraZeneca and Daiichi Sankyo to jointly develop cancer drug

British drugmaker AstraZeneca Plc said late on Thursday it entered into a collaboration deal with Daiichi Sankyo Co Ltd of Japan to develop trastuzumab deruxtecan, a proprietary antibody-drug conjugate for cancer treatment.

Japan's Daiichi Sankyo explores OTC drugs business sale, hires JPMorgan -sources

Japan's Daiichi Sankyo Co is exploring the sale of its over-the-counter drugs (OTC) business and has hired JPMorgan to advise on the potential deal, several people with knowledge of the matter told Reuters.

Japan's Daiichi Sankyo exploring sale of OTC business, hires JP Morgan -sources

Japan's Daiichi Sankyo Co is exploring the sale of its over-the-counter drugs business and has hired JPMorgan to advise on the potential deal, several people with knowledge of the matter told Reuters.

BRIEF-Daiichi Sankyo Co, Roche To Collaborate On New HER2 Low Companion Diagnostic Test

* DAIICHI SANKYO AND ROCHE TO COLLABORATE ON NEW HER2 LOW COMPANION DIAGNOSTIC TEST

BRIEF-Daiichi Sankyo to reorganize Kitasato Daiichi Sankyo Vaccine into specialized manufacturing unit

* Says it plans to reorganize unit Kitasato Daiichi Sankyo Vaccine Co., Ltd. into a unit specializing in manufacturing, effective April 1, 2019

BRIEF-‍Daiichi Sankyo And Darwinhealth Enter Exclusive Research Collaboration For Novel Cancer Target Initiative​

* DAIICHI SANKYO AND DARWINHEALTH ENTER EXCLUSIVE RESEARCH COLLABORATION FOR NOVEL CANCER TARGET INITIATIVE

BRIEF-Daiichi Sankyo completes share repurchase

* Says it accumulatively repurchased 15.7 million shares for 50 billion yen in total as of March 22

BRIEF-Fortis Healthcare Gets Court Order Relating To Daiichi Sankyo Co Case

* GETS COURT ORDER RELATING TO DAIICHI SANKYO COMPANY LIMITED CASE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up